049960 — Cell Biotech Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapSuper Stock

Annual cashflow statement for Cell Biotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	10,383	8,281	6,304	15,127	10,125
Depreciation
Amortisation
Non-Cash Items	-884	1,030	-1,282	-5,195	-2,372
Unusual Items
Other Non-Cash Items
Changes in Working Capital	1,604	-134	-1,111	5,463	-258
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	14,892	12,814	7,815	19,267	11,109
Capital Expenditures	-967	-2,673	-1,686	-1,281	-3,205
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-10,164	-3,996	-3,059	-17,456	7,795
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-11,132	-6,669	-4,745	-18,737	4,590
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-3,858	-7,538	-3,721	-3,741	-3,692
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	260	-1,402	-573	-3,128	12,382